2017 American Transplant Congress
Mycophenolic Acid Needs Ca2+ to Exert Its Anti-inflammatory Action via Shedding of Toll-Like Receptor4 and Tumor Necrosis Factor Receptor 1.
Background Mycophenolic acid (MPA) has been used for many years to prevent transplantation rejection. Recently, it has been investigated for its anti-inflammatory effects. MPA can…2017 American Transplant Congress
Immunosuppressive Regimen Modification Approaches in BK Nephropathy – A Comparative Study.
Department of Medicine, University of Maryland Medical Center, Baltimore, MD
The optimal approach for IS reduction in renal transplant recipients with BKN is not well defined. A number of clinical and in vitro studies suggest…2017 American Transplant Congress
Change in Mycophenolate and Tacrolimus Exposure by Transplant Vintage and Race.
Transplant, MUSC, Charleston, SC
There is strong evidence that both tacrolimus (FK) and mycophenolate (MMF) have improved outcomes in kidney transplantation; yet, the impact of exposure of these immunosuppressants…2017 American Transplant Congress
Impact of Intensive Dosing of Mycophenolate on Pancreas Allograft Survival.
1Pharmacy, UW Health, Madison, WI; 2Transplant Surgery, UW Health, Madison, WI
Purpose: The primary objective was to evaluate the effect of mycophenolate (MPA) dicharge (DC) dose on pancreas allograft (PTX) survival. Secondary endpoints included patient survival…2017 American Transplant Congress
Optimization of Extended-Release Tacrolimus Dose with Mycophenolate Mofetile Based Immunosuppression in De Novo Kidney Transplant Recipients: 2 Years Outcome.
Purpose: Once-daily tacrolimus extended-release formulation (TACER) has been accepted in kidney transplantation, however its optimal dosing are not well determined. We have validated the institutional…2017 American Transplant Congress
Tacrolimus and Mycophenolate Exposure and Subclinical Tubulo-Interstitial Inflammation in Low Immunological Risk Renal Transplants.
The aim is to evaluate the relationship between maintenance immunosuppression, subclinical inflammation (i-score plus t-score) and interstitial fibrosis/tubular atrophy (IF/TA) (ci-score plus ct-score) in paired…2016 American Transplant Congress
Clinical Significance of Mycophenolic Acid Therapeutic Drug Monitoring in Kidney Transplant Recipients.
Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea.
Background: Mycophenolic acid (MPA) is a widely used immunosuppressant to prevent acute rejection in kidney transplant recipients (KTRs). However, clinical significance of MPA therapeutic drug…2016 American Transplant Congress
Concomitant Proton Pump Inhibitor and Mycophenolate Mofetil Use in Renal Transplant Recipients.
Pharmacokinetic (PK) data show reduced mycophenolic acid levels in transplant recipients taking mycophenolate mofetil (MMF) and proton pump inhibitors (PPIs) concomitantly. MMF dosing is not…2016 American Transplant Congress
Mycophenolate Mofetil Dose Reduction Are Associated with the Risk of Acute Rejection and Graft Failure After Renal Transplantation.
Background: Mycophenolate mofetil (MMF) is a highly effective immunosuppressive agent in transplant therapy. Although MMF is generally well tolerated, optimal therapy may be limited by…2016 American Transplant Congress
Benefit of Mycophenolate Mofetile Addition to Very Low Exposure Everolimus and Calcineurine Inhibitor Based Immunosuppression in De Novo Kidney Transplantation with 2 Years Follow-Up.
Purpose: Prospective randomized study of MMF addition to everolimus (EVR) based immunosuppression in order to further reduction of EVR and CNI was evaluated in clinical…
American Transplant Congress abstracts